言語を選択

LRRC15

LRRC15 詳細

英語名	Leucine-rich repeat-containing protein 15	市販薬剤の数	0
治験薬の数	0	ターゲットの別称	LRRC15，Leucine-rich repeat-containing protein 15，hLib，Leucine Rich Repeat Containing 15，Leucine-Rich Repeat Protein Induced By Beta-Amyloid Homolog，LIB，Leucine-Rich Repeat Protein Induced By Beta Amyloid
研究＆開発段階	Preclinical

英語名	Leucine-rich repeat-containing protein 15
ターゲットの別称	LRRC15，Leucine-rich repeat-containing protein 15，hLib，Leucine Rich Repeat Containing 15，Leucine-Rich Repeat Protein Induced By Beta-Amyloid Homolog，LIB，Leucine-Rich Repeat Protein Induced By Beta Amyloid
市販薬剤の数	0
治験薬の数	0
研究＆開発段階	Preclinical

LRRC15 製品リスト

属性
Protein (14)Cell (1)Beads (1)
製品ライブラリ
オンライン (16)
種
Human (7)Mouse (4)Cynomolgus / Rhesus macaque (4)Rat (1)
タグ
His Tag (4)His Tag & Avi Tag (4)Fc Tag (3)Fc Tag & Avi Tag (3)- (2)
マーカー
Unconjugated (7)Biotin-labeled (7)- (2)

製品番号	種	発現システム	製品説明
HOT LR5-H51H3	Human	CHO	Human LRRC15 / LIB Protein, His Tag (MALS verified)
HOT LR5-H52H3	Human	HEK293	Human LRRC15 / LIB Protein, His Tag (MALS verified)
HOT LR5-H82E4	Human	HEK293	Biotinylated Human LRRC15 / LIB Protein, His,Avitag™ (MALS verified)
HOT LR5-M5225	Mouse	HEK293	Mouse LRRC15 / LIB Protein, His Tag (MALS verified)
CHEK-ATP123	Human	HEK293	HEK293/Human LRRC15 Stable Cell Line
LR5-H5257	Human	HEK293	Human LRRC15 / LIB Protein, Fc Tag (MALS verified)
LR5-H82F9	Human	HEK293	Biotinylated Human LRRC15 / LIB Protein, Fc,Avitag™ (MALS verified)
MBS-K079	Human	-	Human LRRC15-coupled Magnetic Beads
LR5-M5253	Mouse	HEK293	Mouse LRRC15 / LIB Protein, Fc Tag (MALS verified)
LR5-M82E6	Mouse	HEK293	Biotinylated Mouse LRRC15 / LIB Protein, His,Avitag™

総数量16

LRRC15バックグランド

LRRC15 (Leucine-rich repeat-containing protein 15) is also known as LIB and hLib. LRRC15 is highly expressed in a variety of solid tumors. LRRC15 was expressed on stromal fibroblasts in many solid tumors (e.g., breast, head and neck, lung, pancreatic) as well as directly on a subset of cancer cells of mesenchymal origin (e.g., sarcoma, melanoma, glioblastoma). LRRC15 expression was induced by TGFβ on activated fibroblasts (αSMA+) and on mesenchymal stem cells. These collective findings suggested LRRC15 as a novel CAF and mesenchymal marker with utility as a therapeutic target for the treatment of cancers with LRRC15-positive stromal desmoplasia or cancers of mesenchymal origin. ABBV-085 is a monomethyl auristatin E (MMAE)-containing antibody–drug conjugate (ADC) directed against LRRC15, and it demonstrated robust preclinical efficacy against LRRC15 stromal-positive/cancer-negative, and LRRC15 cancer-positive models as a monotherapy, or in combination with standard-of-care therapies.